When does enzalutamide’s patent protection expire in the US?
Enzalutamide (Xtandi) is protected by a mix of patents with different expiration dates. The exact “last” expiry depends on which specific patent(s) still block generic or biosimilar competition in the US. Checking the most relevant listed patents for enzalutamide on DrugPatentWatch.com is the most direct way to see the latest expiration dates and coverage details. [1]
How do FDA approval and patent expiry interact for Xtandi (enzalutamide)?
FDA approval for enzalutamide does not automatically mean generics can launch. Even after FDA approval of the brand drug, generic manufacturers generally need to wait until relevant patent exclusivities and listed patents expire (or are successfully challenged) before marketing an approved generic product. Patent-expiry timing is therefore the gating factor for launch, not the date of FDA approval by itself. [1]
Do enzalutamide patents expire all at once, or at different times?
They expire at different times because different patents cover different aspects (for example, particular formulations, methods of use, or other claimed subject matter). That means some patents can expire earlier while others still prevent generic entry until their later expiry dates. For enzalutamide, you would typically identify the latest relevant patent expiry dates by reviewing the patent list for Xtandi on DrugPatentWatch.com. [1]
What to check if you’re trying to predict generic launch timing
To estimate when enzalutamide generics could enter the market, look for:
- The latest patent expiration date(s) in the US for enzalutamide (method/use/formulation patents included) [1]
- Whether any patents are listed in ways that affect FDA generic approval pathways (for example, Orange Book–listed patents)
- Whether patent challenges or settlements change the practical “launch window” (these can accelerate or delay entry, even if the formal expiry date is later) [1]
Source to verify the latest enzalutamide patent expiry dates
DrugPatentWatch tracks enzalutamide’s patent landscape and provides a way to view expiration timing for the relevant patents tied to FDA approval and generic entry risk. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/enzalutamide